Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Ford Motor Company

Western Digital

These brand-name companies are simply too cheap for investors to pass up.

3 Value Stocks That'll Make You Richer in September (and Beyond)

Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.

Merck (MRK) Begins Molnupiravir Study for COVID Prevention

AbbVie

Bristol-Myers

Johnson & Johnson

Now is not the time to sell healthcare. Biopharma offers some of the highest quality bargains in the entire market right now.

4 Blue Chip Bargains In The Biopharma Space

Merck's (MRK) anti-PD-1 therapy, Keytruda, gets full approval from the FDA as a first-line treatment for bladder cancer, after having enjoyed accelerated approval for the indication.

Merck's (MRK) Keytruda Gets Full Approval for Bladder Cancer

Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have initiated the Phase 3 MOVe-AHEAD trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, for the prevention of COVID-19 infection.  The global study enrolls individuals who are at least 18 years of age and reside in the same household as someone with confirmed SARS-CoV-2 infection with symptoms.

Merck To Test Oral Antiviral Candidate For Post-Exposure Prophylaxis Of COVID-19 Infection

Amazon

Aspen Technology Inc

Alibaba

Bayer AG

Baidu

British American Tobacco

Anheuser-Busch InBev

Campbell Soup

Enterprise Products Partners

GlaxoSmithKline

Imperial Brands PLC

Intel

Kellogg

Lockheed Martin

Polaris

Reckitt Benckiser Group PLC

Roche Holding AG

Sanofi

Tencent Holdings Limited

Western Union

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The September 2021 Heat Map

The FDA gave its full approval to Merck & Co Inc's (NYSE: MRK) Keytruda as a treatment for first-line advanced urothelial carcinoma (bladder cancer) patients who are not eligible for platinum-based chemo. Keytruda earned an accelerated nod in first-line locally advanced or metastatic urothelial cancer (UC) patients who were not eligible for chemo back in May 2017.

FDA Extends Full Approval For Merck's Keytruda In 1st-Line Bladder Cancer

Shares of Merck & Co. Inc. MRK, -0.27% and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading.

Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Bio Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Updated Indication for Merck's KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)

FDA Approves Updated Indication for Merck's KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)

Salesforce

Verizon

These underperforming Dow Jones stocks are begging to be bought.

3 of the Dow's Worst-Performing Stocks Over the Trailing Year Are Now Screaming Buys

Air Products and Chemicals

Blackstone Group

Colgate-Palmolive

Gladstone Investment

Coca-Cola

LTC Properties

Main Street Capital

McDonald's

People's United Financial

iShares Preferred and Income Securities ETF 

Shaw Communications

Unum

Exxon Mobil

From May to December 2020, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 equities. Kiplinger article-titles were, 'Dividend15: Our Favorites'; '15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+Year Dividends'; '11 Monthly-Pay Stocks/Funds.'

9 Prime Kiplinger Outstanding September Dividend Dogs To Buy

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Receives Two New Approvals in Japan

Merck's KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan

Merck & Co is not generating enough cash to pay the dividend. Management is increasing R&D spending, which increases the pressure on cash.

Merck: An Unsustainable Dividend And 2 Potential Replacements

Agree Realty

ProShares S&P 500 Dividend Aristocrats ETF

Invesco QQQ

Schwab US Dividend Equity ETF

Universal Health Realty Income Trust

Vanguard Dividend Appreciation ETF

Vanguard Growth ETF

W. P. Carey

It's a great time to be a dividend investor, as the total stock market dividend payout is estimated to reach near pre-pandemic levels this year. Dividend growth stocks manage to capture most of the upside of the stock market while participating in significantly less downside.

5 Dividend Stocks To Act As A Ballast For Your Portfolio

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces VAXNEUVANCE™ Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants

Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the study is unlikely to meet its goal of improving overall survival. The INTR@PID BTC 055 trial examined the drug as a first-line treatment for patients with locally advanced or metastatic biliary tract cancer combined with the chemotherapy drugs cisplatin and gemcitabine.

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial

Merck remains one of the Pharma companies you should be paying the closest attention to at this point. It's one of the the largest and most diversified pharma companies on sale on the entire planet.

Merck - One Of The Best Pharma 'BUYS'

Merck continues to attract me for a long-term investment. The company has seen an eventful year, notably with the spinoff of Organon.

Merck - Murky Non-Keytruda Performance

My pair trade, long JNJ vs. short MRK suggestion has worked out well since December's article. Johnson & Johnson remains a smart accumulation idea, while I currently rate Merck a hold.

Revisiting My Long Johnson & Johnson Vs. Short Merck Call In 2020

The Keytruda-Lenvima combo was recently approved for its second oncology indication.

What This Label Expansion Means for Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Leslie A. Brun Resigns from Merck Board of Directors

Leslie A. Brun Resigns from Merck Board of Directors

Discovery

Discovery Communications

Hillman Capital Management recently disclosed its 13F portfolio updates for the second quarter of 2021, which ended on June 30.

Hillman Capital's Top 2nd-Quarter Buys

News for Merck Stock (MRK)